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vealed, a decrease in peak ground reaction forces of the ex-
perimental leg related to the course of OA (p<0.05). This was
supported by the structural end point measurements. Cartilage
integrity was damaged as reﬂected by an increased macroscopic
( +2.2) and histological score ( +2.0), and by a decreased
proteoglycan content (-20%; all p<0.05). Chondrocyte activity
demonstrated an increase in proteoglycan synthesis rate (+73%)
and release (+64%; both p<0.05). Furthermore, synovial inﬂam-
mation was present macroscopically ( +3.5), and histologically
( +2.0; both p<0.05). This was corroborated by increased syn-
ovial ﬂuid whit blood cell count (WBCC  +1.5) and NO levels
(+30%) increasing during the course of OA.
In the treatment group glycine uptake could be demonstrated:
glycine was found in sufﬁcient amounts in serum and synovial
ﬂuid over time (all time points p<0.05). However, as a result
of treatment no changes in cartilage parameters, osteophyte
formation, and gait were observed. Also, no changes in end stage
inﬂammation and synovial ﬂuid MMP activity were observed.
However, synovial ﬂuid WBCC, and NO production were slightly,
temporarily, but statistically signiﬁcantly (p<0.05) decreased in
the glycine treatment group compared to the placebo group
during the course of OA development.
Conclusions: Glycine, as a potential anti-inﬂammatory agent,
is absorbed by the gastro intestinal tract and reaches serum
and synovial ﬂuid, leading to minor temporary changes in joint
inﬂammation which are not reﬂected by structural and clinical
relevant changes during development of experimentally induced
osteoarthritis in de ACLT-Mx model.
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Purpose: Although topical NSAIDs have been used for many
years, additional supporting evidence of their value is needed.
This study was conducted to determine the efﬁcacy and safety
of topical diclofenac sodium gel 1% (DSG) in knee osteoarthritis
(KOA).
Methods: Patients in this double-blind, randomized, parallel-
group, multicenter 12-week trial had a history of primary KOA
(meeting American College of Rheumatology [ACR] criteria),
diagnosed at least 6 months prior to study entry and symptomatic
in only 1 knee. Patients were randomized to DSG (n=254) or
vehicle (n=238), applied as 4 g to the signal knee 4 times daily.
After a 7-day washout from previous pain medication, baseline
pain on movement was at least 50 mm on a 100-mm visual
analog scale (VAS), and the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain subscale was at
least 9 (out of 20; Likert scale v 3.1). Acetaminophen up to 4
g per day was permitted as rescue medication throughout the
study. Primary efﬁcacy variables at Week 12 included WOMAC
pain subscale (scale = 0 to 20), WOMAC function subscale
(scale = 0 to 68), and global rating of disease (100 mm VAS).
Secondary outcome variables included efﬁcacy at other time
points of the study, success rates based on the Osteoarthritis
Research Society International (OARSI) response criteria, and
use of rescue medication. Safety was assessed at all time points.
Results: Disposition: 77% completed the study. Demographics:
women 2:1 men; 75% white; mean age 60 years (2/3 between
50 and 70); mean pain on movement 71 mm by VAS; mean
WOMAC pain 12. Prior to unblinding, the protocol was amended
to exclude from the efﬁcacy analysis patients with signiﬁcant pain
at baseline in the contralateral knee and/or a decrease in pain on
Table 1. WOMAC pain, WOMAC physical function, and global rating of disease
at Week 12
DSG (n=127) Vehicle (n=119) P-value
WOMAC pain
Mean 5.62 7.38 0.023
Mean  from baseline 5.85 4.68
WOMAC physical function
Mean 19.67 25.72 0.003
Mean  from baseline 17.50 11.80
Patient global
Mean 31.6 41.5 0.018
Mean  from baseline 30.0 22.4
DSG = diclofenac sodium gel 1%; WOMAC = Western Ontario and McMaster
Universities Osteoarthritis Index.
movement over the washout from the screening to the baseline
visit. Table 1 shows the results in the primary efﬁcacy variables
at Week 12. On all important secondary endpoints, patients on
active treatment had a signiﬁcantly better outcome than patients
randomized to vehicle. Table 2 shows response rates based on
the OARSI success criteria.
Table 2. OARSI response, WOMAC pain index normalized to 100-pt scale
OARSI response rate, n (%) DSG, (n=127) Vehicle, (n=119) P-value
Week 1 87 (68.5) 59 (49.6) 0.005
Week 4 94 (74.0) 72 (60.5) 0.043
Week 8 95 (74.8) 70 (58.8) 0.013
Week 12 94 (74.0) 70 (58.8) 0.024
DSG = diclofenac sodium gel 1%; WOMAC = Western Ontario and McMaster
Universities Osteoarthritis index; OARSI = Osteoarthritis Research Society In-
ternational.
The mean number of weeks with no rescue medication use was
signiﬁcantly greater in the DSG group (4.7 weeks) compared
with the vehicle group (3.1 weeks, P=.004).
Adverse events overall were slightly more frequent in the DSG
group than in the vehicle group (60.2% vs 53.8%) with most AEs
being mild or moderate in severity. The incidence of mild gas-
trointestinal disorders was low and comparable in both treatment
groups (DSG: 5.9%, vehicle: 5.0%). Incidence of application site
dermatitis was higher in the DSG group: 4.3% compared with
1.7% in the vehicle group. However, discontinuation rates due to
application site conditions were low in both groups (DSG: 2.0%,
vehicle: 0.8%). Rates of discontinuation of treatment due to AEs
overall were slightly higher in the active treatment group (DSG:
5.1%, vehicle: 3.8%).
Conclusions: In a double-blind, controlled trial, topical diclofenac
sodium gel 1% was superior to vehicle in reducing pain, improv-
ing physical function, and patient global rating of disease for
KOA. DSG was well tolerated.
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Purpose: The sequence of AC-100 is derived from a central 23-
amino acid region of MEPE - an extracellular matrix protein and
is one of the more conserved regions of the molecule. AC-100
has shown speciﬁc activity in vivo to promote tissue appropriate
hard tissue deposition in teeth and in bone. Cell culture studies
have shown AC-100 has potent anabolic activity on osteoblast
and odontoblast precursor cells in vitro. Local PGE2 production
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has been implicated in AC-100 mechanism of action. As ondon-
toblasts and osteoblasts are from the same mesenchymal stem
cell lineage as chondroblasts, an osteochondral defect model
was chosen for a pilot study to investigate the activity of AC-100
on cartilage repair. The goat is well accepted for use in cartilage
repair studies due to the comparable stiﬂe joint size and cartilage
thickness to humans.
Methods: Fifteen skeletally mature female Spanish goats were
used to evaluate the healing response of an osteochondral
femoral condylar defect ﬁlled with a collagen sponge+AC-100 or
+saline. In each goat, a single full thickness (approximately 6
mm in diameter, 6 mm deep) cylindrical defect was created in
the anterior medial femoral condyle of the right hind leg stiﬂe
joint. A cylindrical plug cut from a collagen sponge (CollaPlug;
6mm diameter, 6mm long) was implanted into the lesion site.
The collagen sponge was saturated with the test article (saline;
AC100 2.5, 25mg/application). Post-operative treatments in-
cluded intra-articular injections (0.5mL) of the appropriate test
article into the operated knee joint at 1, 2 and 3 weeks post
surgery. On day 84 (12 weeks) after surgery, two animals from
each group, and on day 168 (24 weeks), three animals from each
group were humanely euthanized. The joints were grossly eval-
uated for speciﬁc changes relative to the medial femoral condyle
and the contacting surfaces. The operated femoral condyle was
analyzed by histology.
Results: There was good correlation between the gross evalua-
tion and the quantitative histological evaluation. The normalized
gross evaluation of the repair tissues showed AC-100 high dose
group to have better healing outcomes (score 2.9, p=0.056 vs.
saline group) than the saline control group (score 0) and the
low dose AC-100 group (score 0.7). At 24 weeks, the high dose
AC-100 group exhibited a better gross outcome (score 6.3), than
the saline control (score 4.0) and low dose AC-100 (score 5.5)
groups. At 12 weeks, the histological evaluation score (max. 28)
of the MFC lesions in the high dose AC-100 group had slightly
better healing outcomes (score 13.5) than the saline control
(score 9.0) and low dose AC-100 (score 10.0) groups, agreeing
with the gross observation scoring. At 24 weeks, the MFC lesions
in the high dose AC-100 group exhibited better outcomes (score
20.3) than the saline control (score 17.5) and low dose AC-100
(score 15.7) groups. There was no evidence of an inﬂammatory
response in any sections examined.
Conclusions: This pilot study showed a clear trend for AC-100
to promote repair of an osteochondral defect. A larger more
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Purpose: Nuclear Factor-κB is a key transcription factor that,
upon activation by pro-inﬂammatory signals like IL-1, directs the
expression of inﬂammatory and catabolic mediators that play an
important role in driving cartilage degradation in OA. Targeting
the signalling pathways that lead to NF-κB activation is a promis-
ing pharmacological approach for the treatment of OA. Essential
oils are complex mixtures of hydrophobic low molecular weight
plant secondary metabolites, composed of a huge diversity of ter-
penoids and/or phenylpropanoids that are promising samples to
screen for biological activities or modulation of molecular targets.
This work aimed at screening and identifying natural inhibitors
of NF-κB activation and subsequent gene expression with po-
tential therapeutic value in the reduction of the inﬂammatory and
catabolic responses of OA.
Methods: Essential oils isolated from plants of the Iberian ﬂora,
as Mentha piperita, Origanum virens, Lavandula luiseri or Ju-
niperus oxycedrus, were screened. The oils showing inhibitory
activity were fractionated by liquid chromatography on a silica
gel column, eluting with n−pentane and diethyl oxide. Each
fraction was then concentrated, analysed by gas chromatogra-
phy and gas chromatography-mass spectroscopy for composition
elucidation and prepared for further screening assays. Normal
human chondrocytes were isolated from the femoral condyles
of cadaveric tissue donors without macroscopic signs of arthritis
and used to evaluate the ability of the essential oils and their
fractions to inhibit IL-1-induced NO production. The human chon-
drocytic cell line, C-28/I2, was used to evaluate NF-κB activation.
Both cell culture types were treated for 30 min with each essen-
tial oil or fraction, in two different dilutions, followed by treatment
with IL-1β (30 ng/ml) for 30 min or 18 h to evaluate, respectively,
NF-κB activation, by detection of the cytoplasmic levels of IκB-α
by western blot, or NO production by the Griess reaction. The
MTT reduction assay was used to rule out cytotoxic effects.
Results: Of the essential oils tested, three reduced IL-1-induced
NO production. The greatest inhibition (79,9 ± 7.9% relatively to
IL-1) was achieved with the lowest dilution (1:5000) of the oil from
the leaves of J. oxycedrus spp. oxycedrus, a common evergreen
shrubthat grows wild throughout the Mediterranean regions. This
essential oil is predominantly composed of monoterpene hydro-
cabons, being α-pinene [2,6,6-trimethyl-bicyclo(3.1.1)hept-3-ene]
the major constituent. The fraction containing α-pinene (over 80%
of relative concentration) reduced signiﬁcantly both IL-1-induced
IκB-α degradation and NO production.
Conclusions: α-pinene is the major component of the essential
oil obtained from the leaves of J. oxycedrus spp. oxycedrus and,
as so, probably accounts for most of its ability to inhibit IL-1-
induced NO production. Moreover, the ability of the α-pinene-
containing fraction to prevent IL-1-induced NF-κB activation and
the subsequent expression of its target genes, namely iNOS,
suggests that α-pinene is promising as an anti-osteoarthritic
drug. Other fractions of this essential oil, particularly those with
oxygen-containing terpenoids, revealed activity, preventing both
IL-1-induced NO production and NF-κB activation, but further
studies are required to identify the active compound(s).
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Purpose: Interleukin-1 receptor antagonist (IL1Ra) attenuates
interleukin-1 (IL1) activity and may diminish osteoarthritis sever-
ity. Intra-articular IL1Ra injection is safe in humans, but the short
joint half-life of small proteins mandates high doses. Conjuga-
tion of a protein drug to elastin-like polypeptides (ELPs) adds a
temperature-sensitive, hydrophobic domain that promotes forma-
